POZEN Logo
Print Page   Close Window

Press Release

POZEN Announces October 4, 2011 Mid-Quarter Update and Financial Guidance Webcast

CHAPEL HILL, N.C., Sep 27, 2011 (BUSINESS WIRE) --

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release a mid-quarter update and financial guidance on October 4, 2011, before the market opens.

The announcement will be followed by a live webcast at 8:30 a.m. (EDT) with an update discussion by POZEN management including financial guidance. The webcast can be accessed on POZEN's website at www.pozen.com and will be archived and available for replay. The mid-quarter update and financial guidance press release will be accessible in the Media section of POZEN's website.

About POZEN

POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years - something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. The lead candidate, PA32540, is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers and has entered Phase 3 clinical trials. POZEN is retaining commercial control of the pipeline assets and will develop a 21st century sales and marketing organization using a new sales force model and digital communications. The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

SOURCE: POZEN Inc.

POZEN
Bill Hodges, 919-913-1030
Chief Financial Officer
or
Stephanie Bonestell, 919-913-1030
Manager, Investor Relations & Public Relations